1-deoxynojirimycin alleviates liver injury and improves hepatic glucose metabolism in db/db mice

Molecules

Volumn 21, Issue 3, 2016, Pages

  Liu, Qingpu ^a   Li, Xuan ^a   Li, Cunyu ^a,b   Zheng, Yunfeng ^a,b   Wang, Fang ^a   Li, Hongyang ^a   Peng, Guoping ^a,b  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization   (China)

Author keywords

1 Deoxynojirimycin; Db db mice; Glucose metabolic enzymes; Hepatic glucose metabolism; Hepatic glycogen; Hepatic insulin sensitivity; Lipid metabolism; Liver; PKB GSK 3

Indexed keywords

1 DEOXYNOJIRIMYCIN; ANTIDIABETIC AGENT; GLUCOSE;

ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; FATTY LIVER; INSULIN RESISTANCE; INTRAVENOUS DRUG ADMINISTRATION; LIPID METABOLISM; LIVER; MALE; METABOLISM; MOUSE; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

1-DEOXYNOJIRIMYCIN; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY LIVER; GLUCOSE; HYPOGLYCEMIC AGENTS; INJECTIONS, INTRAVENOUS; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; MALE; MICE; MICE, TRANSGENIC; MOLECULAR STRUCTURE; SIGNAL TRANSDUCTION;

EID: 84964578167     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules21030279     Document Type: Article

References (62)

1. Zimmet, P.; Alberti, K.G.; Shaw, J. Global and societal implications of the diabetes epidemic. Nature 2001, 414, 782-787. [CrossRef] [PubMed]
2. Kumar, V.; Abbas, A.K.; Fausto, N.; Robbins, S.L.; Cotran, R.S. The skin. In Robbins and Cotran Pathologic Basis of Disease, 7th ed.; Elsevier Saunders: Philadelphia, PA, USA, 2005; pp. 1194-1195.
3. DeBruyne, L.K.; Whitney, E.N.; Pinna, K. Nutrition and Diet Therapy, 7th ed.; Thomson Wadsworth: Belmont, CA, USA, 2008.
4. Min, K.H.; Kim, H.J.; Jeon, Y.J.; Han, J.S. Ishige okamurae ameliorates hyperglycemia and insulin resistance in C57BL/KsJ-db/db mice. Diabetes Res. Clin. Pract. 2011, 93, 70-76. [CrossRef] [PubMed]
5. Andallu, B.; Suryakantham, V.; Lakshmi Srikanthi, B.; Reddy, G.K. Effect of mulberry (Morus indica L.) therapy on plasma and erythrocyte membrane lipids in patients with type 2 diabetes. Clin. Chim. Acta. 2001, 314, 47-53. [CrossRef]
6. Naowaboot, J.; Pannangpetch, P.; Kukongviriyapan, V.; Kukongviriyapan, U.; Nakmareong, S.; Itharat, A. Mulberry leaf extract restores arterial pressure in streptozotocin-induced chronic diabetic rats. Nutr. Res. 2009, 29, 602-608. [CrossRef] [PubMed]
7. Kuriyama, C.; Kamiyama, O.; Ikeda, K.; Sanae, F.; Kato, A.; Adachi, I.; Imahori, T.; Takahata, H.; Okamoto, T.; Asano, N. In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. Bioorg. Med. Chem. 2008, 16, 7330-7336. [CrossRef] [PubMed]
8. Asano, N.; Yamashita, T.; Yasuda, K.; Ikeda, K.; Kizu, H.; Kameda, Y.; Kato, A.; Nash, R.J.; Lee, H.S.; Ryu, K.S. Polyhydroxylated alkaloids isolated from mulberry trees (Morus alba L.) and silkworms (Bombyx mori L.). J. Agric. Food Chem. 2001, 49, 4208-4213. [CrossRef] [PubMed]
9. Asano, N. Glycosidase inhibitors: Update and perspectives on practical use. Glycobiology 2003, 13, 93R-104R. [CrossRef] [PubMed]
10. Miyahara, C.; Miyazawa, M.; Satoh, S.; Sakai, A.; Mizusaki, S. Inhibitory effects of mulberry leaf extract on postprandial hyperglycemia in normal rats. J. Nutr. Sci. Vitaminol. 2004, 50, 161-164. [CrossRef] [PubMed]
11. Asano, N. Sugar-mimicking glycosidase inhibitors: Bioactivity and application. Cell. Mol. Life Sci. 2009, 66, 1479-1492. [CrossRef] [PubMed]
12. Yagi, M.; Kouno, T.; Aoyagi, Y.; Murai, H. The structure of moranoline, a peperidine alkaloid from Morus species. Nippon Nogei Kagaku Kaishi 1976, 50, 571-572. [CrossRef]
13. Liu, Q.; Li, X.; Li, C.; Zheng, Y.; Peng, G. 1-Deoxynojirimycin Alleviates Insulin Resistance via Activation of Insulin Signaling PI3K/AKT Pathway in Skeletal Muscle of db/db Mice. Molecules 2015, 20, 21700-21714. [CrossRef] [PubMed]
14. Rizza, R.A. Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: Implications for therapy. Diabetes 2010, 59, 2697-2707. [CrossRef] [PubMed]
15. Sharabi, K.; Tavares, C.D.; Rines, A.K.; Puigserver, P. Molecular pathophysiology of hepatic glucose production. Mol. Aspects Med. 2015, 46, 21-33. [CrossRef] [PubMed]
16. Shen, S.C.; Chang, W.C.; Chang, C.L. An extract from wax apple (Syzygium samarangense (Blume) Merrill and Perry) effects glycogenesis and glycolysis pathways in tumor necrosis factor-treated FL83B mouse hepatocytes. Nutrients 2013, 5, 455-467. [CrossRef] [PubMed]
17. Benhamed, F.; Denechaud, P.D.; Lemoine, M.; Robichon, C.; Moldes, M.; Bertrand-Michel, J.; Ratziu, V.; Serfaty, L.; Housset, C.; Capeau, J.; et al. The lipogenic transcription factor chrebp dissociates hepatic steatosis from insulin resistance in mice and humans. J. Clin. Invest. 2012, 122, 2176-2194. [CrossRef] [PubMed]
18. Fabbrini, E.; Sullivan, S.; Klein, S. Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications. Hepatology 2010, 51, 679-689. [CrossRef] [PubMed]
19. Ferre, P.; Foufelle, F. Hepatic steatosis: A role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes. Metab. 2010, 12 (Suppl. 2), 83-92. [CrossRef] [PubMed]
20. Burra, P. Liver abnormalities and endocrine diseases. Best Pract. Res. Clin. Gastroenterol. 2013, 27, 553-563. [CrossRef] [PubMed]
21. Zheng, T.; Yang, X.; Wu, D.; Xing, S.; Bian, F.; Li, W.; Chi, J.; Bai, X.; Wu, G.; Chen, X.; et al. Salidroside ameliorates insulin resistance through activation of a mitochondria-associated AMPK/PI3K/Akt/GSK3+ pathway. Br. J. Pharmacol. 2015, 172, 3284-3301. [CrossRef] [PubMed]
22. Doi, K.; Kojima, T.; Fujimoto, Y. Mulberry leaf extract inhibits the oxidative modification of rabbit and human low density lipoprotein. Biol. Pharm. Bull. 2000, 23, 1066-1071. [CrossRef] [PubMed]
23. Tsuduki, T.; Nakamura, Y.; Honma, T.; Nakagawa, K.; Kimura, T.; Ikeda, I.; Miyazawa, T. Intake of 1-deoxynojirimycin suppresses lipid accumulation through activation of the -oxidation system in rat liver. J. Agric. Food Chem. 2009, 57, 11024-11029. [CrossRef] [PubMed]
24. Ann, J.Y.; Eo, H.; Lim, Y. Mulberry leaves (Morus alba L.) ameliorate obesity-induced hepatic lipogenesis, fibrosis, and oxidative stress in high-fat diet-fed mice. Genes Nutr. 2015, 10, 1-13. [CrossRef] [PubMed]
25. Altamirano, J.; Bataller, R. Alcoholic liver disease: Pathogenesis and new targets for therapy. Nat. Rev. Gastroenterol. Hepatol. 2011, 8, 491-501. [CrossRef] [PubMed]
26. Floreani, N.A.; Rump, T.J.; Abdul Muneer, P.M.; Alikunju, S.; Morsey, B.M.; Brodie, M.R.; Persidsky, Y.; Haorah, J. Alcohol-induced interactive phosphorylation of Src and toll-like receptor regulates the secretion of inflammatory mediators by human astrocytes. J. Neuroimmune Pharmacol. 2010, 5, 533-545. [CrossRef] [PubMed]
27. Tilg, H.; Day, C.P. Management strategies in alcoholic liver disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2007, 4, 24-34. [CrossRef] [PubMed]
28. Inzaugarat, M.E.; Ferreyra Solari, N.E.; Billordo, L.A.; Abecasis, R.; Gadano, A.C.; Chernavsky, A.C. Altered phenotype and functionality of circulating immune cells characterize adult patients with nonalcoholic steatohepatitis. J. Clin. Immunol. 2011, 31, 1120-1130. [CrossRef] [PubMed]
29. Martel, C.; Esposti, D.D.; Bouchet, A.; Brenner, C.; Lemoine, A. Non-alcoholic steatohepatitis: New insights from omics studies. Curr. Pharm. Biotechnol. 2012, 13, 726-735. [CrossRef] [PubMed]
30. Braunersreuther, V.; Viviani, G.L.; Mach, F.; Montecucco, F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J. Gastroenterol. 2012, 18, 727-735. [CrossRef] [PubMed]
31. Wieckowska, A.; Papouchado, B.G.; Li, Z.; Lopez, R.; Zein, N.N.; Feldstein, A.E. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2008, 103, 1372-1379. [CrossRef] [PubMed]
32. Tang, C.C.; Huang, H.P.; Lee, Y.J.; Tang, Y.H.; Wang, C.J. Hepatoprotective effect of mulberry water extracts on ethanol-induced liver injury via anti-inflammation and inhibition of lipogenesis in C57BL/6J mice. Food Chem. Toxicol. 2013, 62, 786-796. [CrossRef] [PubMed]
33. Magnoni, L.J.; Vraskou, Y.; Palstra, A.P.; Planas, J.V. Amp-activated protein kinase plays an important evolutionary conserved role in the regulation of glucose metabolism in fish skeletal muscle cells. PLoS ONE 2012, 7, e31219. [CrossRef] [PubMed]
34. Agius, L. Role of glycogen phosphorylase in liver glycogen metabolism. Mol. Aspects Med. 2015, 46, 34-45. [CrossRef] [PubMed]
35. Basu, A.; Basu, R.; Shah, P.; Vella, A.; Johnson, C.M.; Jensen, M.; Nair, K.S.; Schwenk, W.F.; Rizza, R.A. Type 2 diabetes impairs splanchnic uptake of glucose but does not alter intestinal glucose absorption during enteral glucose feeding: Additional evidence for a defect in hepatic glucokinase activity. Diabetes 2001, 50, 1351-1362. [CrossRef] [PubMed]
36. Oosterveer, M.H.; Mataki, C.; Yamamoto, H.; Harach, T.; Moullan, N.; van Dijk, T.H.; Ayuso, E.; Bosch, F.; Postic, C.; Groen, A.K.; et al. LRH-1-dependent glucose sensing determines intermediary metabolism in liver. J. Clin. Investig. 2012, 122, 2817-2826. [CrossRef] [PubMed]
37. Ros, S.; Garcia-Rocha, M.; Calbo, J.; Guinovart, J.J. Restoration of hepatic glycogen deposition reduces hyperglycaemia, hyperphagia and gluconeogenic enzymes in a streptozotocin-induced model of diabetes in rats. Diabetologia 2011, 54, 2639-2648. [CrossRef] [PubMed]
38. Lee, Y.S.; Cha, B.Y.; Saito, K.; Yamakawa, H.; Choi, S.S.; Yamaguchi, K.; Yonezawa, T.; Teruya, T.; Nagai, K.; Woo, J.T. Nobiletin improves hyperglycemia and insulin resistance in obese diabetic ob/ob mice. Biochem. Pharmacol. 2010, 79, 1674-1683. [CrossRef] [PubMed]
39. Hu, S.; Chang, Y.; Wang, J.; Xue, C.; Li, Z.; Wang, Y. Fucosylated chondroitin sulfate from sea cucumber in combination with rosiglitazone improved glucose metabolism in the liver of the insulin-resistant mice. Biosci. Biotechnol. Biochem. 2013, 77, 2263-2268. [CrossRef] [PubMed]
40. Sundaresan, A.; Harini, R.; Pugalendi, K.V. Ursolic acid and rosiglitazone combination alleviates metabolic syndrome in high fat diet fed C57BL/6J mice. Gen. Physiol. Biophys. 2012, 31, 323-333. [CrossRef] [PubMed]
41. John, S.; Weiss, J.N.; Ribalet, B. Subcellular localization of hexokinases I and II directs the metabolic fate of glucose. PLoS ONE 2011, 6, e17674. [CrossRef] [PubMed]
42. Sun, L.; Shukair, S.; Naik, T.J.; Moazed, F.; Ardehali, H. Glucose phosphorylation and mitochondrial binding are required for the protective effects of hexokinases I and II. Mol. Cell. Biol. 2008, 28, 1007-1017. [CrossRef] [PubMed]
43. Holyoak, T.; Zhang, B.; Deng, J.; Tang, Q.; Prasannan, C.B.; Fenton, A.W. Energetic coupling between an oxidizable cysteine and the phosphorylatable N-terminus of human liver pyruvate kinase. Biochemistry 2013, 52, 466-476. [CrossRef] [PubMed]
44. Cortes-Cros, M.; Hemmerlin, C.; Ferretti, S.; Zhang, J.; Gounarides, J.S.; Yin, H.; Muller, A.; Haberkorn, A.; Chene, P.; Sellers,W.R.; Hofmann, F. M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth. Proc. Natl. Acad. Sci. USA 2013, 110, 489-494. [CrossRef] [PubMed]
45. Bouché, C.; Serdy, S.; Kahn, C.R.; Goldfine, A.B. The cellular fate of glucose and its relevance in type 2 diabetes. Endocr. Rev. 2004, 25, 807-830. [CrossRef] [PubMed]
46. Jung, U.J.; Lee, M.K.; Jeong, K.S.; Choi, M.S. The hypoglycemic effects of hesperidin and naringin are partly mediated by hepatic glucose-regulating enzymes in C57BL/KSJ-db/db mice. J. Nutr. 2004, 134, 2499-2503. [PubMed]
47. Li, Y.G.; Ji, D.F.; Zhong, S.; Lv, Z.Q.; Lin, T.B.; Chen, S.; Hu, G.Y. Hybrid of 1-deoxynojirimycin and polysaccharide from mulberry leaves treat diabetes mellitus by activating PDX-1/insulin-1 signaling pathway and regulating the expression of glucokinase, phosphoenolpyruvate carboxykinase and Glucose-6-phosphatase in alloxan-induced diabetic mice. J. Ethnopharmacol. 2011, 134, 961-970. [PubMed]
48. Friedman, J.E.; Sun, Y.; Ishizuka, T.; Farrell, C.J.; McCormack, S.E.; Herron, L.M.; Hakimi, P.; Lechner, P.; Yun, J.S. Phosphoenolpyruvate carboxykinase (GTP) gene transcription and hyperglycemia are regulated by glucocorticoids in genetically obese db/db transgenic mice. J. Biol. Chem. 1997, 272, 31475-31481. [CrossRef] [PubMed]
49. Waltner-Law, M.E.;Wang, X.L.; Law, B.K.; Hall, R.K.; Nawano, M.; Granner, D.K. Epigallocatechin gallate, a constituent of green tea, represses hepatic glucose production. J. Biol. Chem. 2002, 277, 34933-34940. [CrossRef] [PubMed]
50. Li, Y.G.; Ji, D.F.; Zhong, S.; Lin, T.B.; Lv, Z.Q.; Hu, G.Y.; Wang, X. 1-Deoxynojirimycin inhibits glucose absorption and accelerates glucose metabolism in streptozotocin-induced diabetic mice. Sci. Rep. 2013, 3, 1377. [CrossRef] [PubMed]
51. Liu, H.Y.; Fang, M.; Zhang, Y.Q. In vivo hypoglycaemic effect and inhibitory mechanism of the branch bark extract of the mulberry on STZ-induced diabetic mice. Sci. World J. 2014, 2014, 614265. [CrossRef] [PubMed]
52. Bollen, M.; Vandebroeck, A.; Stalmans,W. 1-Deoxynojirimycin and related compounds inhibit glycogenolysis in the liver without affecting the concentration of phosphorylase a. Biochem. Pharmacol. 1988, 37, 905-909. [CrossRef]
53. Embi, N.; Rylatt, D.B.; Cohen, P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-amp-dependent protein kinase and phosphorylase kinase. Eur. J. Biochem. 1980, 107, 519-527. [CrossRef] [PubMed]
54. Grimes, C.A.; Jope, R.S. The multifaceted roles of glycogen synthase kinase 3 in cellular signaling. Prog. Neurobiol. 2001, 65, 391-426. [CrossRef]
55. Plyte, S.E.; Hughes, K.; Nikolakaki, E.; Pulverer, B.J.;Woodgett, J.R. Glycogen synthase kinase-3: Functions in oncogenesis and development. Biochim. Biophys. Acta 1992, 1114, 147-162. [CrossRef]
56. Ross, S.E.; Erickson, R.L.; Hemati, N.; MacDougald, O.A. Glycogen synthase kinase 3 is an insulin-regulated C/EBP+ kinase. Mol. Cell. Biol. 1999, 19, 8433-8441. [CrossRef] [PubMed]
57. McManus, E.J.; Sakamoto, K.; Armit, L.J.; Ronaldson, L.; Shpiro, N.; Marquez, R.; Alessi, D.R. Role that phosphorylation of gsk3 plays in insulin and wnt signalling defined by knockin analysis. EMBO J. 2005, 24, 1571-1583. [CrossRef] [PubMed]
58. Cohen, P.; Frame, S. The renaissance of GSK3. Nat. Rev. Mol. Cell Biol. 2001, 2, 769-776. [CrossRef] [PubMed]
59. Schenk, S.; Saberi, M.; Olefsky, J.M. Insulin sensitivity: Modulation by nutrients and inflammation. J. Clin. Investig. 2008, 118, 2992-3002. [CrossRef] [PubMed]
60. Barillas, R.; Friehs, I.; Cao-Danh, H.; Martinez, J.F.; del Nido, P.J. Inhibition of glycogen synthase kinase-3 improves tolerance to ischemia in hypertrophied hearts. Ann. Thorac. Surg. 2007, 84, 126-133. [CrossRef] [PubMed]
61. Li, Y.; Xu, S.; Mihaylova, M.M.; Zheng, B.; Hou, X.; Jiang, B.; Park, O.; Luo, Z.; Lefai, E.; Shyy, J.Y.; et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab. 2011, 13, 376-388. [CrossRef] [PubMed]
62. Lee, H.J.; Ok, H.M.; Kwon, O. Protective effects of Korean red ginseng against alcohol-induced fatty liver in rats. Molecules 2015, 20, 11604-11616. [CrossRef] [PubMed]